Enfusion (NYSE:ENFN – Get Free Report) is scheduled to release its earnings data before the market opens on Thursday, May 9th. Analysts expect Enfusion to post earnings of $0.04 per share for the quarter. Enfusion has set its FY 2024 guidance at EPS.Investors interested in listening to the company’s conference call can do so using this link.
Enfusion (NYSE:ENFN – Get Free Report) last posted its earnings results on Tuesday, March 12th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $46.49 million during the quarter, compared to analyst estimates of $45.56 million. Enfusion had a net margin of 3.45% and a return on equity of 10.30%. On average, analysts expect Enfusion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Enfusion Stock Performance
ENFN stock opened at $9.76 on Tuesday. Enfusion has a one year low of $7.37 and a one year high of $11.56. The firm’s fifty day moving average is $9.18 and its 200 day moving average is $9.16. The firm has a market cap of $1.25 billion, a PE ratio of 121.94, a P/E/G ratio of 2.79 and a beta of 0.97.
Analyst Ratings Changes
Check Out Our Latest Stock Report on Enfusion
Enfusion Company Profile
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Further Reading
- Five stocks we like better than Enfusion
- Insider Trading – What You Need to Know
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Value Stocks You Can Buy Before They Become Big
- How to Buy Cheap Stocks Step by Step
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.